Navigation Links
New Parkinson's Drug Draws Mixed Reviews
Date:9/23/2009

Researchers split on whether it slowed disease progression in trial

WEDNESDAY, Sept. 23 (HealthDay News) -- A study to see whether a new drug can stop the progression of Parkinson's disease has produced results that have drawn sharply differing reactions from neurologists.

The drug, rasagiline (Azilect), was approved in 2006 by the U.S. Food and Drug Administration on the basis of studies showing that it reduced Parkinson's symptoms such as trembling and slowed motion. The new study, reported in the Sept. 24 issue of the New England Journal of Medicine, was designed to determine whether the drug also acts on the underlying nerve deterioration that causes the disease.

"In our heart, what we are hoping for is neuroprotection," said study author Dr. C. Warren Olanow, a professor of neurology and neuroscience at Mount Sinai School of Medicine, in New York City.

To distinguish the effect on symptoms from the hoped-for effect on the underlying disease, "we used a totally new study design, to see if it is disease-modifying," Olanow explained.

The study enlisted 1,176 people with previously untreated Parkinson's disease who were seen at medical centers around the world. At the start, half took daily doses of either 1 milligram or 2 milligrams of rasagiline for 36 weeks, while the other half took a placebo. After that, all the participants took either 1 milligram or 2 milligrams of rasagiline for another 36 weeks.

A complex system to measure the treatment effects showed an apparent improvement in the participants who took the 1-milligram doses but not in those taking the 2-milligram doses.

"It did something to affect the course of the disease," Olanow said. "We don't know why, but we are entitled to speculate."

His speculation is based on a detailed study of the 25 percent of participants who showed the greatest benefit. "What I think is right is that the higher dose had a greater effect on symptoms than the lower dose, so that masked our ability to detect its effect on disease progression," Olanow said. "We thought that this floor effect was why we couldn't see a difference."

Olanow was enthusiastic about the results. "This doesn't prove unequivocally that it [rasagiline] is neuroprotective, but there is no other rational explanation for the results," he said. "This is good news for Parkinson's patients."

Asked if he would prescribe the drug for that reason, Olanow said, "Yes, I would personally prescribe it."

A much more skeptical response came from Dr. William J. Weiner, chair of neurology at the University of Maryland, who took part in the study.

"The authors were very careful in the paper not to indicate that they had shown neuroprotection," Weiner said. "The tone of the article itself is moderate."

The methods used to determine trial results need scrutiny, he said. "They used a lot of very fancy mathematical models, some of which had not been used before," Weiner said. "Most neurologists wouldn't understand the mathematical models they used. Research neurologists don't deal with equations about the slope of curves."

And the end results were not impressive, he maintained. "The difference reported in the study is less than two points on a scale that has 150 points," Weiner said.

The reason why the lower dose worked, and the higher one didn't? "It simply could be luck," he said.

While rasagiline can provide benefits in reducing symptoms of early Parkinson's disease, Weiner said he was worried that "patients will be given what I believe to be false hopes" by the new study.

"It has mild symptomatic effects, but I do not prescribe this drug for neuroprotection and this study doesn't convince me to do that," Weiner said.

Several of the study authors have received consulting or lecturing fees from pharmaceutical companies, including Teva, the maker of Azilect.

More information

Learn about Parkinson's disease from the U.S. National Institute of Neurological Disorders and Stroke.



SOURCES: C. Warren Olanow, M.D., professor, neurology and neuroscience, Mount Sinai School of Medicine, New York City; William J. Weiner, M.D., professor and chair, neurology, University of Maryland, Baltimore; Sept. 24, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Food Addicts Convention Draws 800 Members from 31 States, 5 Nations Around the World
2. Misuse of Pain Medication Draws Heightened Concerns
3. Tevas Forum Draws Key Pennsylvania Healthcare Leaders
4. Allscripts User Conference Draws 2,700, Sets Attendance Record
5. Boston Cardinal OMalley Withdraws Caritas Christi From Potential Abortion Scandal
6. Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel
7. Leading US Pediatric Hospital Draws First Dose with RIVA System
8. All Hands On Sweepstakes Thanks, Draws Industry to Web Site
9. Max Muscle Sports Nutrition Franchising Draws Record Interest
10. Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
11. Dr Timothy Huckabee Free Day of Dental Care Draws a Crowd
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Parkinson's Drug Draws Mixed Reviews
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: